MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer

Scott Koenig discusses the data on the Phase 3 SOPHIA study.<br /><br />About MacroGenics, Inc.<br /><br />MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative mo... Author: Annual-Meeting Added: 06/07/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts